Enzymotec (ENZY) Misses Q4 EPS by 3c; Guides FY16 EPS Below Views

Enzymotec (NASDAQ: ENZY) reported Q4 EPS of $0.07, $0.03 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $13.3 million versus the consensus estimate of $14.01 million.

GUIDANCE:

Enzymotec sees FY2016 EPS of $0.25 - $0.30, versus the consensus of $0.56.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance